mva-bn
Trade name: JYNNEOS
Approved
Sep 24, 2019
The smallpox vaccine is used to prevent smallpox infection caused by the variola virus. It is the first vaccine to have been developed against a contagious disease. In 1796, British physician Edward Jenner demonstrated that an infection with the relatively mild cowpox virus conferred immunity against the deadly smallpox virus. Cowpox served as a natural vaccine until the modern smallpox vaccine emerged in the 20th century. From 1958 to 1977, the World Health Organization (WHO) conducted a global vaccination campaign that eradicated smallpox, making it the only human disease to be eradicated. Although routine smallpox vaccination is no longer performed on the general public, the vaccine is still being produced for research, and to guard against bioterrorism, biological warfare, and mpox. — Wikipedia
Clinical trial activity
22 trials · 25 clinical orgs · 1 marketing orgs
Earliest trial started Nov 2, 1999 (NCT00002261)
Timeline
1990s
- Jan 1, 1999
Earliest Phase 1 Sponsor(trial)
2000s
- Jan 1, 2002
Earliest Phase 2 Sponsor(trial)
2010s
- Jan 1, 2015
Bavarian Nordic — Earliest Phase 3 Sponsor(trial)
- Sep 24, 2019
Bavarian Nordic — Earliest FDA Approval
- Sep 24, 2019
Bavarian Nordic — NDA Secondary Org
- Sep 24, 2019
Bavarian Nordic — NDA Organization
Indications
Approved for
Studied for
- Child · Phase 3
- Dermatitis, Atopic · Phase 2
- Healthy Volunteers · Phase 3
- HIV Infections · Phase 1
- Infant · Phase 3
- Infant, Newborn · Phase 3
- Mpox, Monkeypox · Phase 4
- Postpartum Period · Phase 3
- Pregnancy · Phase 3
- Safety · Phase 3
- Smallpox · Phase 3
- Smallpox Vaccine · Phase 1
- Vaccination · Phase 3
- Vaccinia · Early Phase 1
- Virus Diseases · Early Phase 1
Mechanism of action
- Unspecified targetOTHER
Biological vaccine - induces immune response
- Cowpox virusImmunity, active
Cowpox virus immunity, active
Approval history
- approvedSep 24, 2019
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSmallpox vaccine ↗
- ChEMBLCHEMBL2108688 ↗
Also known as
- modified vaccinia ankara - bavarian nordic (mva-bn) virus
- mva-b
- mva bn
- mva-bn
- smallpox vaccine
- smallpox vaccine
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07253675 | Phase 2 | Dec 31, 2025 | China National Biotec Group Co., Ltd, University of Kinshasa |
| NCT07199569 | Phase 2 | Oct 27, 2025 | Bavarian Nordic, ICON |
| NCT06839989 | Phase 2 | Aug 4, 2025 | Institute of Tropical Medicine, Belgium |
| NCT06844500 | Phase 3 | Jun 23, 2025 | ace africa, Bavarian Nordic, European and Developing Countries Clinical Trials Partnership (EDCTP), PENTA Foundation, University of Antwerp, University of Kinshasa |
| NCT06844487 | Phase 3 | May 29, 2025 | ace africa, Bavarian Nordic, European and Developing Countries Clinical Trials Partnership (EDCTP), PENTA Foundation, University of Antwerp, University of Kinshasa |
| NCT06549530 | Phase 2 | Oct 16, 2024 | Bavarian Nordic, Coalition for Epidemic Preparedness Innovations |
| NCT06366672 | Early Phase 1 (Phase 1) | Jun 10, 2024 | Washington University in St. Louis |
| NCT05734508 | Phase 4 | Mar 23, 2023 | Government of Congo, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT05740982 | Phase 2 | Mar 22, 2023 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT05512949 | Phase 2 | Sep 7, 2022 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT05438953 | N/A | Jul 12, 2022 | Assistance Publique - Hôpitaux de Paris |
| NCT04957485 | Phase 2 | Oct 21, 2021 | Department of Defense, Medical CBRN Defense Consortium (MCDC), SIGA Technologies |
| NCT03699124 | Phase 3 | Apr 1, 2019 | Bavarian Nordic, Department of Health and Human Services, University of Alabama, Birmingham |
| NCT01913353 | Phase 3 | Mar 1, 2015 | Bavarian Nordic, United States Army |
| NCT00565929 | Phase 1 | Sep 1, 2008 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00679497 | Phase 1 | Jun 1, 2008 | University of Barcelona |
| NCT00316602 | Phase 2 | Jul 1, 2006 | Bavarian Nordic, National Institute of Allergy and Infectious Diseases (NIAID), University of Kentucky |
| NCT00316524 | Phase 2 | May 1, 2006 | Bavarian Nordic, Ludwig Maximilians University, National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00050518 | Phase 2 | Dec 11, 2002 | National Institute of Allergy and Infectious Diseases (NIAID) |
| NCT00189943 | Phase 1 | Apr 1, 2001 | Bavarian Nordic, PharmPlanNet Contract Research GmbH |
Organizations
Research & Development (25)
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Bavarian Nordic | For profit | NDA2 | Sep 24, 2019 |
| Bavarian Nordic | For profit | NDA | Sep 24, 2019 |